Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | BLM | P54132 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274573 | 0.90 | THRB (0.45) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL1742705 | 0.90 | THRB (0.45) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL11742941 | 0.86 | THRB (0.42) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL10884344 | 0.82 | LMNA (0.45) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL169323 | 0.79 | LMNA (0.54) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL5319562 | 0.79 | LMNA (0.54) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL6694580 | 0.79 | SCN9A (0.37) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL16671244 | 0.78 | PTPRA (0.38) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL5320318 | 0.76 | KDM4E (0.54) | THRBLMNAKMT2AMEN1BLM | |
| SCHEMBL607092 | 0.76 | KDM4E (0.54) | THRBLMNAKMT2AMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080003284-A1 | LEVOTHYROXINE COMPOSITIONS AND METHOS | FRANZ G A | 2008-01-03 | — | — | US | disclosed |
| US-7101569-B2 | Methods of administering levothyroxine pharmaceutical compositions | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-09-05 | — | — | US | disclosed |
| EP-1474103-A1 | LEVOTHYROXINE COMPOSITIONS AND METHODS | King Pharmaceuticals, Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004014318-A2 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003070217-A1 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003061557-A2 | LEVOTHYROXINE PHARMACEUTICAL COMPOSITIONS, METHODS OF MAKING AND METHODS OF ADMINISTRATION | KING PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6555581-B1 | .00005-5 wt% of a levothyroxine salt, >/= 50 wt% of flat needle shape microcrystalline cellulose with bulk density of .10-.23 g/cm3 and conductivity of < 200 mu s/cm and .5-30 wt% disintegrating agent; immediate release for treating thyroids | JONES PHARMA, INC. | 2003-04-29 | — | — | US | disclosed |
| WO-2003028624-A2 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003013441-A2 | LEVOTHYROXINE COMPOSITIONS AND METHODS | KING PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003284-A1 | LEVOTHYROXINE COMPOSITIONS AND METHOS | TPO, TRHDE, THRA | THRB 7/4885LMNA 2944/4885KMT2A 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.